Peptide Kappa Opioid Receptor Ligands: Potential for Drug Development
Journal Title: The AAPS Journal - Year 2009, Vol 11, Issue 2
Abstract
While narcotic analgesics such as morphine, which act preferentially through mu opioid receptors, remain the gold standard in the treatment of severe pain, their use is limited by detrimental liabilities such as respiratory depression and drug dependence. Thus, there has been considerable interest in developing ligands for kappa opioid receptors (KOR) as potential analgesics and for the treatment of a variety of other disorders. These include effects mediated both by central receptors, such as antidepressant activity and a reduction in cocaine-seeking behavior, and activity resulting from the activation of peripheral receptors, such as analgesic and anti-inflammatory effects. While the vast majority of opioid receptor ligands that have progressed in preclinical development have been small molecules, significant advances have been made in recent years in identifying opioid peptide analogs that exhibit promising in vivo activity. This review will focus on possible therapeutic applications of ligands for KOR and specifically on the potential development of peptide ligands for these receptors.
Authors and Affiliations
Jane V. Aldrich, Jay P. McLaughlin
Keywords
Related Articles
- EP ID EP681478
- DOI 10.1208/s12248-009-9105-4
- Views 74
- Downloads 0
Compartmental Analysis and its Manifold Applications to Pharmacokinetics
The online version of this article (doi:10.1208/s12248-009-9160-x) contains supplementary material, which is available to authorized users.
Structure–Activity Relationships and Quantitative Structure–Activity Relationships for Breast Cancer Resistance Protein (ABCG2)
Breast cancer resistance protein (ABCG2), the newest ABC transporter, was discovered independently by three groups in the late 1990s. ABCG2 is widely distributed in the body with expression in the brain, intestine, and l...
Pharmacodynamics-Mediated Drug Disposition (PDMDD) and Precursor Pool Lifespan Model for Single Dose of Romiplostim in Healthy Subjects
The objective of this study was to characterize the pharmacokinetics and pharmacodynamics (PK-PD) of romiplostim after single-dose administration in healthy subjects. The mean serum romiplostim concentrations (PK data) a...
Viewing chemokines as a third major system of communication in the brain
There is irrefutable proof that opioids and other classes of centrally acting drugs have profound effects on the immune system. Evidence is mounting that products of the immune system, such as chemokines, can reciprocall...
Futility Rules in Bioequivalence Trials with Sequential Designs
The online version of this article (doi:10.1208/s12248-013-9540-0) contains supplementary material, which is available to authorized users.